Navigation Links
Study Sheds Light on Painkillers' Heart Risk
Date:11/3/2008

Cox-2 drugs, like Celebrex, less safe than Cox-1 drugs, like naproxen, study says

MONDAY, Nov. 3 (HealthDay News) -- The increased risk of heart attack that comes with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) to treat arthritis pain is directly related to the specific pain-causing molecule they act against, a new study finds.

"We found a significant correlation between the degree of inhibition in vitro [in the laboratory] of whole blood cox-2, but not whole blood cox-1," said the report by researchers in Spain and Italy.

Cox-1 and cox-2 are different forms of cyclooxygenase, an enzyme whose activity increases inflammation and pain. Older NSAIDs, such as ibuprofen and naproxen, act primarily against cox-1. A newer generation of NSAIDs that act against cox-2 reduce the gastrointestinal bleeding, pain and inflammation that are major side effects of the cox-1 drugs, but they have been found to increase the risk of heart attack and stroke.

Three cox-2 inhibitor NSAIDs have been marketed in the United States. Two of them -- Bextra and Vioxx -- were withdrawn from the market earlier this decade because of their association with an increased risk of heart attack and stroke. A third cox-2, Celebrex, remains available, but with a label warning of cardiovascular risk.

All NSAIDs increase heart risk, according to the new study of 8,852 people who had heart attacks. And the increase was related to both the dosage and the length of time the drugs were taken. But the risk was increased by 18 percent by drugs acting primarily against cox-1, compared to a 60 percent increase for those with the greatest cox-2 activity.

The findings were published in the Nov. 11 issue of the Journal of the American College of Cardiology.

Dr. Michael E. Farkouh, director of clinical trials at the Mount Sinai Cardiovascular Institute in New York City, said the new study "lends support to the theory that each drug must be judged on an individual basis."

The cox-2 impact is an important factor in NSAID cardiovascular risk, but other drug characteristics, some not discussed in the new study, are important as well, Farkouh said.

"What they [the study authors] don't account for is the rise in blood pressure," he said. "Drugs that raise blood pressure are the most toxic. Also important is the half-life of a drug -- how long it stays in the system. They [the authors] don't address that head-on, but they do look at slow release as a variable, which is associated with half-life."

Then there are the possible interactions of a drug with aspirin, which is also widely used for pain relief, Farkouh noted. "The take-home message to patients is that when they are given one of these drugs, they should assess it in terms of all these variables," he said.

Farkouh's view is that "naproxen is the safest drug we have. Its risk profile appears to be consistently low." And while "the jury is still out on Celebrex, it still can have a role in patients at high risk of gastrointestinal bleeding," he said.

Dr. James Brophy, a professor of medicine and epidemiology at McGill University in Montreal who has done NSAID studies, said the new findings "are totally consistent with what has been seen both in clinical trials and observational studies."

The study is yet another signal from a large, real-world database that NSAID use can lead to increased cardiovascular risk, Brophy said.

More information

To learn more about NSAIDs, visit the U.S. Food and Drug Administration.



SOURCES: Michael E. Farkouh, M.D., director, clinical trials, Mount Sinai Cardiovascular Institute, New York City; James Brophy, M.D., professor, medicine and epidemiology, McGill University, Montreal; Nov. 11, 2008, Journal of the American College of Cardiology


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. GSU study first to confirm long-term benefits of morphine treatment in infants
2. Study finds fears of HIV transmission in families with infected parent
3. Moores UCSD Cancer Center studying novel leukemia vaccine for high-risk patients
4. Derma Sciences Enrolls First Patient in DSC127 Phase II Study
5. Study links primary insomnia to a neurochemical abnormality in young and middle-aged adults
6. Landmark UCLA study finds aggresive, personalized treatment increases kidney cancer patient survival
7. Study reports Double Balloon Endoscopy useful for diagnosis and treatment of obscure GI bleeding
8. Patience during stalled labor can avoid many C-sections, UCSF study shows
9. UNC Lineberger launches 44-county study of breast cancer in black women
10. Pioneer(R) Surgical Technologys NuBac(R) Nucleus Replacement Device Wins FDA Approval for IDE Pivotal Study
11. Study Finds Preventative Diabetes Care Reduces Amputation Occurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important to take certain medications ... from Austin, Texas, has identified a solution. , She developed a prototype for MOTION ... As such, it eliminates the need to turn on a light when taking medication ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder ... of ElderCounsel, a national organization of elder law and special needs planning attorneys. “Membership ... rules. It also provides a forum to network with elder law attorneys nationwide,” said ...
(Date:10/13/2017)... ... 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out ... free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting ... children of all ages; it is a non-competitive, non-timed event, which is all about ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... , Oct. 12, 2017   Divoti USA ... up to the standard of the latest FDA requirements, which stipulates ... Anyone in need of Medical ID jewelry such as ... Jewelry are engraved in terms of the new FDA ... Divoti offers this ...
(Date:10/11/2017)... PARK, Calif. , Oct. 11, 2017  BioPharmX ... national scientific team that developed an innovative way to ... quantity of the delivery of new drugs. ... 2017 Fall Clinical Dermatology Conference will show how researchers ... General Hospital, Harvard Medical School used a suite of ...
(Date:10/11/2017)... 2017  True Health, a leader in integrated ... during National Breast Cancer Awareness month to educate ... Research recently published ... more than 10 million American women are at ... or BRCA2 and have not had testing. These mutations ...
Breaking Medicine Technology: